Clinical TrialAug 4, 2026, 08:34 AM
Entera Bio EB613 Phase 2 Data Selected for ASBMR Plenary Poster
AI Summary
Entera Bio announced that post-hoc data from its Phase 2 clinical trial of EB613, an oral treatment for osteoporosis, has been selected for two presentations at the ASBMR 2026 Annual Meeting, including a prestigious Plenary Poster Presentation. The data showed markedly enhanced anabolic effects in postmenopausal women with osteoporosis at high risk of fracture. The company plans a Phase 3 trial with approximately 750 patients to support a potential New Drug Application.
Key Highlights
- EB613 Phase 2 post-hoc data selected for two ASBMR 2026 presentations.
- Includes a Plenary Poster Presentation at the ASBMR 2026 Annual Meeting.
- EB613 is an oral PTH(1-34) tablet for osteoporosis treatment.
- Phase 2 study showed enhanced anabolic effects in postmenopausal women.
- Data consistent with published subcutaneous teriparatide at 6 months.
- Company plans a Phase 3 trial with ~750 patients for NDA submission.
Price Impact
More from ENTX